 Home > Active Ingredient News > Blood System > J INTERN MED: What is the risk of thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica?

J INTERN MED: What is the risk of thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica?

 Last Update: 2022-01-21
 Source: Internet
 Author: User

Tags

1 2 copper

epa risk assessment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are systemic inflammatory diseases that primarily affect older women
.

The purpose of this study was to compare the risk of thromboembolic events and retinal vascular occlusion in patients with osteoarthritis (OA) with GCA and / or PMR
.

Thrombosis _

In this retrospective study, a total of 1535 patients with GCA, 10265 patients with PMR, and 1203 patients with a combination of the two diseases, and 39009 age- and sex-matched patients with OA were included
.

The researchers calculated and assessed the occurrence of pulmonary embolism (PE), deep vein thrombosis (DVT), arterial thromboembolism (ATE), central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO) over time rate ratio (IRR)

Patients with GCA and a combination of both diseases had higher IRRs for all thromboembolic events compared with patients with OA
.

Patients with comorbidities (HR 2.

CONCLUSIONS: GCA, PMR, and patients with a combination of the two diseases have the same risk of thromboembolic events
.

The researchers' findings may help predict the risk of thromboembolic events based on disease phenotype

Patients with GCA, PMR, and comorbidities had the same risk of thromboembolic events

Original source:

Despina Michailidou, et al.

Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States Leave a Comment

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.